Financing to support advancement of CREATE's repeat dose capable CD19 targeted in vivo CAR-T therapy for autoimmune disease into the clinic, expansion of its dual CAR CD19 x BCMA program, and continued progress across the oncology portfolio Round co-led by existing investors Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners, reflecting conviction in CREATE's clinical trajectory and platform Ron Philip joins as Executive Chairman; Brian Cuneo of ARCH Venture Partners and Tom

May 13, 2026 -- Whitehawk Therapeutics, Inc. (the "Company" or "Whitehawk") (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that it has entered into a securities purchase agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity ("PIPE") financing that is expected

Tessera Therapeutics has created an experimental gene editing drug for sickle cell disease that could compete with commercial cell therapies but is delivered as an infusion — no complex cell engineering or chemotherapy preconditioning required. The closely watched and well-funded startup said that a single infusion of its experimental therapy edited the hemoglobin gene, which is mutated in the disease, in 85% of red blood cells in monkeys. That level of editing is almost triple the 30% threshol

Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achieving MMR by 24 weeks in mature, heavily pretreated 80 mg QD Phase 1b cohort In patients who previously received asciminib, cumulative MMR rate was 52%, with 38% of patients achieving MMR by 24 weeks ELVN-001 maintained a favorable safety and tolerability profile with 141 patients enrolled and a median treatment duration of ~32 weeks EHA presentation will include updated data with additional patients

May 12, 2026 -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that two additional participants have been successfully dosed in the fourth cohort of its FDA-approved Phase I/IIa clinical trial evaluating CMND-100 (MEAI) for the treatment of moderate to s

May 12, 2026 -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for F351 (hydronidone) as a treatment for chronic hepatitis B (CHB)-induced liver fibrosis, which is liver damage resulting from t

The research collaboration will be the first ever to focus on space-based drug formulation that could result in therapies for patients. May 13, 2026 -- Varda Space Industries today announced a collaboration with United Therapeutics Corporation (Nasdaq: UTHR) to explore the use of microgravity to develop improved formulations of treatments for rare pulmonary disease. Through the collaboration, Varda and United Therapeutics will conduct pharmaceutical processing of small molecule medicines for p

Rigel gets hands on Pfizer's recently-approved breast cancer drug Bayer cuts early-stage assets from pipeline Superior weight loss in Wegovy HD early responders 'First-of-its-kind' collab aims to incubate new biotechs Rigel gets hands on Pfizer's recently-approved breast cancer drug Having signalled their intent last year to find a US commercialisation partner for vepdegestrant, Pfizer and Arvinas reached an agreement with Rigel Pharmaceuticals on Tuesday to both market and further develop the

May 13, 2026 -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced topline clinical data on ABI-6250, an investigational oral hepatitis D virus (HDV) entry inhibitor, will be presented in a poster presentation at the European Association for the Study of the Liver (EASL) Congress taking place May 27-30, 2026, in Barcelona, Spain. “We are pleased to present additional Phase 1a data on ABI-6250 at

May 12, 2026 -- Virginia Cancer Specialists announced today its participation as a leading clinical trial site in a landmark study evaluating daraxonrasib, a first‑in‑class targeted oral therapy for patients with previously treated, advanced KRAS‑mutated pancreatic cancer. Results from the Phase 1/2 trial, published recently in The New England Journal of Medicine, demonstrated exceptional disease control in a cancer historically resistant to targeted treatment. Positive Phase 3 results reported